Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAcibadem University
About this trial
This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Between the ages of 18 and 65,
No severe hearing and vision problems,
Can speak and understand Turkish,
Easy to communicate with,
Disqualifiers
Having any problem that prevents you from communicating cognitively, emotionally and verbally,
Obstructive sleep abnormalities,
Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.),
With metabolic abnormalities,
Trial design
Design model
Parallel
Treatments tested in this trial
STANDART CARE
Other interventionRoutine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.
STANDART CARE & FAN THERAPY
Other interventionIn addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of \~15 cm. Dyspnea severity and number of episodes will be recorded during this period.
Treatment groups
110 Participants
are divided into 2 treatment groupsGroup A: Standard Care (Control Group)Active comparator 1 intervention
Group B: Standard Care + Fan Therapy (Experimental Group)Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Incidence of ticagrelor-associated dyspnea
The proportion of participants who experience dyspnea within 120 minutes following ticagrelor administration will be recorded.
Time frame
Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Percentage of participants (%)Secondary outcomes
1
Time to onset of ticagrelor-associated dyspnea
The time interval between ticagrelor administration and the first reported dyspnea episode will be measured in minutes.
Time frame
Time Frame: Within 120 minutes after ticagrelor administration (T1-T4) Unit of Measure: Minutes (min)Other outcomes
1
Severity of ticagrelor-associated dyspnea
Dyspnea severity will be assessed using the Modified Borg Dyspnea Scale (0-10) at T1 (baseline), T2 (30 min), T3 (60 min), and T4 (120 min) after ticagrelor administration. Higher scores indicate greater symptom severity.
Time frame
Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Score (0-10)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov